A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Inclusion Criteria:

- Men and women Aged ≥18 years

- Hospitalized subjects who have confirmed COVID-19 infection and have evidence of
pneumonia:

- Subjects who are eligible for diagnosis/evaluation to chest X-ray or chest CT

- Women of childbearing potential (including women in post menopause for less than 2
years) must use a medically acceptable forms of birth control and agree to continue
its use during the study

- Subjects (or legally authorized representative) should be able to understand and agree
to comply with the clinical trial and to provide a written consent document prior to
initiation of any study procedure

Exclusion Criteria:

- Subjects who have a record of HIV or AIDS

- Subject has a serious chronic disease

- Active bleeding or ongoing clinical condition deemed at high risk of bleeding
contraindicating anticoagulant treatment

- Pregnant or lactating females

- Subjects with liver cirrhosis whose Child-Pugh score is B or C

- Subjects who have liver disease abnormalities with ALT or AST > 5 times ULN

- Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving
hemodialysis or hemofiltration)

- QTcB or QTcF >500ms

- Subjects who have clinically significant ventricular arrhythmias (ventricular
tachycardia, ventricular fibrillation) in medical history

- Subjects with rapidly deteriorating clinical condition or low likelihood to complete
the study according to the investigator's opinion

- Subjects who are not appropriate for the study, as the investigator's opinion

- Subjects who have hypersensitivity to the investigational drug

- Subjects participated in any other clinical trial (including drugs for the treatment
of COVID-19) 3 months prior to screening